Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

Second Line Chemo or Tarceva: Which is Better for Advanced NSCLC Patients without an EGFR Mutation?
Dr West
Author
Howard (Jack) West, MD

Dr. Mark Socinski covered the TAILOR trial, an Italian study directly comparing second line Taxotere (docetaxel) to Tarceva (erlotinib) in advanced NSCLC patients without an EGFR mutation, in the ASCO Lung Cancer Highlights program.  However, as a preview to his comments you'll find in the podcast here, I'll share that he wasn't fond of the trial or the questionable value of the results from it.  

Still, the trial is among the ones likely to be most discussed in the field of lung cancer from ASCO 2012, so it's worth hearing what it showed, along with an expert perspective of how to interpret it.  Below, you'll find the audio and video versions of the podcast along with the transcript and figures.

Dr. Socinski ASCO LC Highlights 2012 TAILOR Trial Audio Podcast

Dr. Socinski ASCO LC Highlights 2012 TAILOR Trial Transcript

Dr. Socinski ASCO LC Highlights 2012 TAILOR Trial Figs

We'll finish Dr. Socinski's presentation of ASCO Highlights in Lung Cancer with his summary of some work in small cell lung cancer. Look for that soon.

 

 

Next Previous link

Previous PostNext Post

Related Content

Online Community

An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components:

  1. The antibody, which serves as the “horse,” specifically targets a protein found on cancer...

Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...

The prefix “oligo–” means few. Oligometastatic (at diagnosis) Oligoprogression (during treatment)

There will be a discussion, “Studies in Oligometastatic NSCLC: Current Data and Definitions,” which will focus on what we...

Radiation therapy is primarily a localized treatment, meaning it precisely targets a specific tumor or area of the body, unlike systemic treatments (like chemotherapy) that affect the whole body.

The...

Biomarkers are genetic mutations (like EGFR, ALK, KRAS, BRAF) or protein levels (like PD-L1) in tumor cells that help guide personalized treatment, especially NSCLC, directing patients to targeted therapies or immunotherapies...

Hi Stan!  So good to hear from you.  I'm sorry for the late response.  I too have been out of town with family and missed your post, probably because I was...

It is so good to hear from you!  And I am so happy to hear that your holidays have been good and that you are doing well.  It sounds like your...

Recent Comments

JOIN THE CONVERSATION
Biomarkers
By JanineT GRACE … on
Radiation Therapy
By JanineT GRACE … on
Oligometastatic vs Oligoprogression
By JanineT GRACE … on
Hi Stan!! and happiest of holidays!
By dbrock on